BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. I… Read more
BioXcel Therapeutics Inc (BTAI) - Total Liabilities
Latest total liabilities as of September 2025: $133.71 Million USD
Based on the latest financial reports, BioXcel Therapeutics Inc (BTAI) has total liabilities worth $133.71 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioXcel Therapeutics Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how BioXcel Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioXcel Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of BioXcel Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cedergrenska AB
ST:CEDER
|
Sweden | Skr286.10 Million |
|
JITF Infralogistics Limited
NSE:JITFINFRA
|
India | ₹49.46 Billion |
|
Main Street Financial Services Corp
OTCQX:MSWV
|
USA | $1.37 Billion |
|
Kartal Yenilenebilir Enerji Uretim AS
IS:KARYE
|
Turkey | TL931.18 Million |
|
Eternit S.A
SA:ETER3
|
Brazil | R$569.41 Million |
|
NTG Clarity Networks Inc
PINK:NYWKF
|
USA | $17.26 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down BioXcel Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioXcel Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioXcel Therapeutics Inc (2015–2024)
The table below shows the annual total liabilities of BioXcel Therapeutics Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $131.44 Million | +0.94% |
| 2023-12-31 | $130.21 Million | +0.88% |
| 2022-12-31 | $129.08 Million | +626.30% |
| 2021-12-31 | $17.77 Million | +34.23% |
| 2020-12-31 | $13.24 Million | +39.41% |
| 2019-12-31 | $9.50 Million | +103.80% |
| 2018-12-31 | $4.66 Million | +99.40% |
| 2017-12-31 | $2.34 Million | +606.04% |
| 2016-12-31 | $331.00K | +89.14% |
| 2015-12-31 | $175.00K | -- |